Azole resistant Candida glabrata vulvovaginitis treated with boric acid

Savini, Vincenzo; Catavitello, Chiara; Bianco, Azaira; Balbinot, Andrea; D’Antonio, Francesco; D’Antonio, Domenico

doi:10.1016/j.ejogrb.2009.06.020

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search performed in PubMed and Scopus retrieved a total of 36 and 158 search results, respectively, among which 14 studies (2 RCTs, 8 case series, and 4 case reports) were identified as eligible for inclusion in this review. 13,[16][17][18][19][20][21][22][23][24][25][26][27][28] No additional studies were identified through hand-searching of references. The selection of studies to be included in this review is depicted graphically in Figure 1.…”

Section: Selected Studiesmentioning

confidence: 99%

“…In 13 of 14 studies, there were available data about dosage and duration of treatment. 13,[16][17][18][19][20][21][22][23][24][25][26]28 Boric acid was used as vaginal suppositories at a dose of 600 mg either once or twice per day for 14 days. Different pathogens were identified, including C. albicans, C. glabrata, Candida tropicalis, and Candida parapsilosis.…”

Section: Selected Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

Iavazzo

Gkegkes

Zarkada

et al. 2011

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

Section: Selected Studiesmentioning

confidence: 99%

Section: Selected Studiesmentioning

confidence: 99%

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

Iavazzo

Gkegkes

Zarkada

et al. 2011

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…Most C. guilliermondii strains show sensitivity to amphotericin B (Table 3); 9,12,[20][21][22]29,[48][49][50][51]53,[56][57][58] although the yeast is intrinsically less susceptible to polyenes (along with C. glabrata, C. krusei, Candida lusitaniae and Candida rugosa) than other Candida species (it has been sometimes labelled as polyene-tolerant), few reports have documented resistance to such compounds and widespread of this has not been observed so far. 9,12,[20][21][22]29,[48][49][50][51]53,[56][57][58][59][60] Of interest, Barchiesi et al reported data about killing curve assays performed with amphotericin B. The author found the drug to behave as a fungistatic compound against three C. guilliermondii isolates, at the MIC.…”

Section: Polyenesmentioning

confidence: 99%

“…Most C. guilliermondii strains show sensitivity to amphotericin B (Table 3); 9,12,20–22,29,48–51,53,56–58 although the yeast is intrinsically less susceptible to polyenes (along with C. glabrata , C. krusei , Candida lusitaniae and Candida rugosa ) than other Candida species (it has been sometimes labelled as polyene‐tolerant), few reports have documented resistance to such compounds and widespread of this has not been observed so far 9,12,20–22,29,48–51,53,56–60 …”

Section: Susceptibility and Treatmentmentioning

confidence: 99%

What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast

Savini

Catavitello

Onofrillo

et al. 2010

Mycoses

Self Cite

View full text Add to dashboard Cite

Candida guilliermondii is an uncommon isolate throughout most of the world, the behaviour of which as an environmental fungus, a human saprophyte and an agent of serious infections has been emphasised over the years. Notably, illnesses caused by this pathogen mostly involve compromised cancer hosts and commonly lead patients to unfavourable outcomes. It is of concern that the yeast may acquire or inherently express reduced in vitro sensitivity to all antifungal classes, although widespread resistance has not yet been described, and poor correlation exists between MICs and clinical outcome. However, the organism appears as constitutively less susceptible to polyenes and echinocandins than other yeast-like fungi, so that the emergence of such pathogen in the clinical settings is of concern and may appear as a new challenge in the context of mycoses and antifungal therapy.

show abstract

Boric Acid for the Treatment of Vaginitis: New Possibilities Using an Old Anti‐Infective Agent: A Systematic Review

Lærkeholm Müller,

Damsted Petersen,

Saunte

2024

Dermatologic Therapy

View full text Add to dashboard Cite

Introduction. Increasing microbial resistance to conventional pharmaceuticals calls for nonpharmaceutical treatments of vaginitis. This systematic review summarizes the efficacy of the antiseptic agent boric acid (BA) as a treatment option for microbial vaginitis in comparison to conventional therapies and proposes clinical recommendations. Materials and Methods. PubMed and Embase were searched for “boric acid” and “microbial vaginitis.” A protocol was registered on PROSPERO (CRD42020160146). Inclusion criteria included clinical trials, observational and interventional studies, including case series/reports. Exclusion criteria included in vitro and animal studies, non‐English language, and no BA treatment outcome. Primary outcomes included microbial, clinical, and complete cure. Secondary outcomes included adverse events, relapse/reinfection rates, evidence levels, microorganisms, treatment regimens, and follow‐up time. Data were extracted to a predefined Excel sheet. Results. Of 195 identified unique articles, 54 were retrieved and 41 met our inclusion criteria. Heterogeneity precluded the conduction of a meta‐analysis. Conclusion. An average cure rate of 76% was found for vulvovaginal candidiasis BA treatment. Recurrent bacterial vaginosis was controlled with BA and 5‐nitroimidazole with promising results. Maintenance BA was equal to maintenance oral itraconazole therapy in vulvovaginal candidiasis and bacterial vaginosis in a retrospective study. Prolonged BA monotherapy cured three of six recurrent Trichomonas infections. Adverse events (7.3%) were typically mild and temporary. Based on our findings and the rising antimicrobial therapy resistance, we suggest intravaginal BA 600 mg/day for 2 weeks for (recurrent) vulvovaginal candidiasis and 600 mg/day for 2‐3 weeks for recurrent bacterial vaginosis. Rare resistant Trichomonas infections can be treated with BA 600 mg × 2/day for months and in combination with oral antimicrobials. We suggest a maintenance regimen of BA 600 mg × 2/week for recurrent vulvovaginal candidiasis. In case of resistant bacterial vaginosis, we suggest BA 600 mg × 2‐3/week. Data on maintenance therapy and BA treatment of bacterial vaginosis and trichomoniasis are however limited.

show abstract

Azole resistant Candida glabrata vulvovaginitis treated with boric acid

Cited by 4 publications

References 5 publications

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast

Boric Acid for the Treatment of Vaginitis: New Possibilities Using an Old Anti‐Infective Agent: A Systematic Review

Contact Info

Product

Resources

About